Multi-Profile Hospital For Active Treatment Dr. Stamen Iliev AD
- Address
- lock Available on a paid plan
Respiratory Tract Disease Therapeutics
The Department of Pneumology and Phthisiatrics at Multi‑Profile Hospital For Active Treatment Dr. Stamen Iliev AD concentrates on Respiratory Tract Diseases, especially Chronic Obstructive Pulmonary Disease (COPD) and various forms of asthma. Ongoing studies aim to test new inhaled combinations and assess long‑term safety of emerging biologics, with the ultimate goal of improving lung function and reducing severe exacerbations.
- Combination triple therapy versus dual bronchodilator outcomes
- Long‑term safety of itepekimab in COPD
- Efficacy of CHF6001 as add‑on to triple therapy
- Evaluation of dexpramipexole for severe eosinophilic asthma
- Depemokimab treatment in COPD with type‑2 inflammation
With five dedicated investigators, the site integrates clinical expertise and patient‑centered research to advance therapeutic options for chronic respiratory conditions across the region.
Viral Lung Infection and Immunization Research
This center also targets Virus Diseases, focusing on influenza, SARS‑CoV‑2 (COVID‑19), and other severe viral lung infections. Trials evaluate novel vaccine candidates, antiviral agents, and immunomodulators to lower hospitalization rates and improve recovery for high‑risk populations.
- mRNA‑1010 candidate influenza vaccine versus licensed comparator
- High‑dose trivalent influenza vaccine efficacy in seniors
- Tozorakimab for viral lung infection requiring supplemental oxygen
- Molnupiravir efficacy in non‑hospitalized COVID‑19 adults at high risk
- Assessment of vaccine‑induced immune response in adults ≥50 years
The hospital’s multidisciplinary approach supports rapid evaluation of preventive and therapeutic strategies against emerging respiratory viruses.
Integrated Asthma & COPD Precision Medicine
By bridging the two therapeutic domains, the department advances precision medicine for patients with severe eosinophilic asthma and COPD characterized by type‑2 inflammation. Research seeks to identify biomarkers and test targeted biologics that can modify disease pathways and reduce the burden of chronic airway disease.
- Depemokimab early‑therapy trials in COPD with type‑2 inflammation
- Dexpramipexole long‑term extension for severe eosinophilic asthma
- Biomarker‑driven assessment of triple inhaled therapy efficacy
- Comparative study of CHF5993 versus CHF1535 in COPD
- Evaluation of novel anti‑eosinophil agents in asthma
Leveraging its regional expertise, the site delivers innovative trial designs that aim to personalize treatment and enhance quality of life for individuals suffering from complex respiratory disorders.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 therapeutic areas and 15 of 27 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 5 by active trials.
- 1AstraZeneca AB2active
lock +4 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Chiesi Farmaceutici S.p.A.3trials
lock +2 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 476 other sites in Bulgaria
Therapeutic Area Benchmark — Bulgaria
Select a therapeutic area to compare against other sites in Bulgaria.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Bulgaria
Market Share
Country: Bulgaria
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Multi-Profile Hospital For Active Treatment Dr. Stamen Iliev AD
lock Showing 1 of 15 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Safety Evaluation of Fluticasone Propionate/Salbutamol Sulfate Combination in Asthma Patients Aged 12 and Older: A Randomized, Double-Blind, Placebo-Controlled Trial | Teva Branded Pharmaceutical Products R&D LLC | Phase III | Recruiting | Jul 2025 | — |
IMP list
lock Showing 1 of 27 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| A/Victoria/4897/2022 (H1N1)Pdm09-Like Strain (A/Victoria/4897/2022, Ivr-238) | 3 | Unknown | 2023-10-20 | 2025-10-20 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.